In the current study, histopathological evaluation of dorsal skin lesions demonstrated that decreased inflammatory cell infiltration was observed in the CAPCS-treated group, suggesting that one of the therapeutic effects of CAPCS for AD could be due to AMPs, which improved skin barrier function and reduced the inflammatory response to relieve pruritus in AD. The gene discussed is ADSL; the disease is Alzheimer disease.